ArThec

PEARL
WE RESTORE MOBILITY

Restoring the function  of joint surfaces using  tissueengineering

Thanks to the PEARL procedure, performed at an early stage of the development of the degenerative disease, it will be possible to completely regenerate the cartilage.
learn more
Thanks to the regeneration of cartilage defects, the disease will not progress and the need for arthroplasty (implantation of a joint endoprosthesis) will not occur.
learn more
Innovative Method
Proven results
Experienced Team
Patented therapy

No effective strategy for treatment young, active patients with cartilage leasions.

  • The total degenerative patient population is increasing
  • The age at which the first surgical treatment is performed is decreasing
  • There are no effective treatments for small to medium articular cartilage lesions.

in 2030

The first THA (total hip arthroplasty) performed in younger patients will constitute 52%

The first TKA (total knee arthroplasty) 55%

Osteoarthritis (OA)

Is a disease characterized by joint  pain and dysfunction caused by  the progressive and irreversible  loss of joint cartilage.

 

At an advanced stage of the  disease, it becomes necessary  touseanendoprosthesis.Removal  of the joint means its permanent  destruction and the  final  loss  of periarticular bone tissue.

In the case of disease progression and  periimplant tissue degeneration,the next  stage is an even more extensive excision of the tissues and theimplantation

of larger implant – which usually ends with a permanent disabilityafter revision  surgeries.

By 2050

130 million patients will be suffering

from osteoarthritis

40 million will be disabled

It is significant that the disease affects  younger and younger patients,  analyzing data so far

Value of the global endoprosthesis market:

2019 - USD 19.32 billion
2027 - USD 29.79 billion
5.6% CAGR

There is no effective therapy for degenerative joint disease

Worldwide, 9.6% of men and 18% of women over the age of 60 have symptoms of osteoarthritis.

80% of them suffer from limited movement  and 25% areunable to perform basic life  activities.

learn more
Disadvantages of existing solutions

Disadvantages of traditional methods (endoprostheses)

The prosthesis does not rebuild into tissue. Its implantation destroys bone and cartilage irreversibly.

Progressive tissue lysis around the endoprosthesis.

Inability to fill and restore the tissue after loosening the implant.

In the case of peri-prosthetic fractures, it is necessary to replace with extensive damage to the bones and surrounding tissues.

Endoprosthesis loosening - revisions of endoprostheses lead to the loss of bone tissue and surrounding structures, which results in permanent disability.

Inability to reproduce the full range of motion. Inability to return to full fitness.

Hip prosthesis - risk of dislocation, Hip and knee prosthesis - complex periprosthetic bone fractures.

Age and health restrictions.

Significant risk of infection (not only perisurgical).

The need for revision surgery that appears along with the implantation of an endoprosthesis in younger age groups 45-55 (1- 3 per patient) - increased risk of complications.

Disadvantages of available biological methods

Lack of technology to restore full-thick and stable hyaline cartilage.

Limited effectiveness compared to traditional methods (endoprothesis).

Possibility to treat small cartilage defects.

Unknown effectiveness in people over 55 years of age.

High cost of therapy.

In the United States, only 0.4% of all surgically treated patients undergo regenerative treatment , but this group is gradually growing.

First Round - Completed
  • Objectives – optimizationand validation of the method.
  • Acquired capital – EUR 230 thousand.
  • Duration of work – 8 quarters.
Second Round - Present
  • Objectives – conducting research hospital exception (HEATMP) and clinical trial preparation.
  • Capital demand – EUR 230 thousand.
  • Duration of work – 4 quarters.
Third Round
  • Objectives – clinical tial and ATMP registration
  • Capital demand EUR 3.8 million
  • Duration of work – 14 quarters
team

meet Our Experienced team

Grzegorz Stefański

Chairman of the Board
Doctor of medicine. A graduate of GUMED, SGH, UG. For 25 years associated with the pharmaceutical and biotechnology industry. Managing biotechnology companies, including those listed on the Warsaw Stock Exchange. He developed and introduced innovative medical solutions to the market. Creator of several patents. Co-founder of the following companies: Mabion, Biophage, Tridens, Urteste, Human Biome Institute. Co-founder of the Aligo Alfa investment fund

Dr. Eng. Sławomir Jaros

Executive MBA
PhD in biotechnology from the Polish Academy of Sciences. Executive MBA completed at the University of Lodz in cooperation with the University of Maryland. An expert in managing projects related to the development of innovative therapies, including the most modern drug classes in the world. Relating projects from the Start up phase to the WIG. Experience in building companies, managing large units, including companies listed on the Warsaw Stock Exchange. Building the Company on the WSE from New Connect to WIG40 within eight years. Winner of awards and distinctions, including the Young Wolf of the Stock Exchange 2015.

Dr Grzegorz Sobieraj

A graduate of the Faculty of Medicine at the Medical University of Lodz. Orthopedics and traumatology specialist. Member of the ESSKA , ICRS ,ESSSE , Polish Arthroscopic Society, Polish Orthopedic Society. A pioneer in the field of innovative joint operating procedures. Manager of the PCZ Orthopedic Department in Brzeziny. Medical Director of the Medical Hospital of the St. John of God Hospital in Łódź. Head pshysician of the orthopedic ward in the Ortho Sport Clinic Private Hospital in Poland.

Julita Balcerek

AbA graduate of the Faculty of Biotechnology at the University of Wrocław. PhD student at the Medical University of Lodz. Experience in managing projects related to the development of innovative therapies (from their direct implementation at the stage of research and development in the field of molecular biology and protein biochemistry to supervision of the process of creating and submitting registration documentation at EMA). Experience in building and managing a team of the Research and Development Department. Experience in managing teams implementing parts of a joint project - development of a biotechnological drug (manufacturing, quality control, research and development, clinical trials, quality assurance and regulation). Creation and management of quality systems (GMP, GLP, GCP).

Tomasz Kostuch

A graduate of the Gdańsk University of Technology (Faculty of Electronics) and the University of Gdańsk (Faculty of Management). For 25 years associated with the financial industry. He participated in the implementation of many innovative projects and implementations of modern technologies. For 10 years he has been involved in strategic consulting and creating financial policy in dynamically developing enterprises Co-founder of the companies: Maximus Finance, Tridens, Urteste, Human Biome Institute.
Address

Starodworska 1
80-180 Gdansk, Poland

E-mail

arthec@arthec.eu

ARTHEC

WRITE US
A MESSAGE